Clinical trial intelligence powered by machine learning.
FDA approval probability predictions for 475,000+ drug programs from 35+ data sources.
Featured Insight
Options-implied sentiment diverges from ML predictions for 13 single-asset biotechs this week.
475K+
Drug Programs Scored
104
Predictive Features
96.8%
Honest AUC (no reg. features)
35+
Data Sources, Updated Daily
Per-Drug POS Scores
Every drug program scored individually with probability of FDA approval. See exactly which features drive each prediction.
Weekly Playbook
Probability-weighted catalyst events for the coming week. Expected outcomes based on POS scores, options data, and historical event studies.
Market Divergence
Compare ML-predicted approval probabilities against options-implied market sentiment for pipeline-concentrated companies.
AdCom Intelligence
FDA advisory committee member profiling. Voting patterns, industry payments, academic credentials, and predicted panel outcomes.
Options Intelligence
ATM implied volatility, IV percentile, and put/call ratios for 300+ biotech tickers. Updated daily from Polygon.io.
Catalyst Calendar
Upcoming Phase 2/3 readouts, PDUFA dates, and AdCom meetings with POS scores and conference overlap detection.
Drug Screener
Filter 475K+ programs by POS, phase, FDA designations, therapeutic area, sponsor type, and clinical trial characteristics.
What-If Scenarios
Toggle features like Breakthrough Therapy or double-blind design to see real-time POS changes. Shareable via URL.
ETF Pipeline Analysis
Map biotech ETF holdings (XBI, IBB, ARKG) against drug pipeline data. See which ETFs have the strongest clinical pipelines.
Sponsor & Management Intel
Company pipeline depth, historical approval rates, executive backgrounds, and clinical trial execution track records.
Competitive Landscape
Compare drugs targeting the same indication. See how many competitors are in each phase and which have the strongest profiles.
Regulatory Tracker
FDA actions, EMA approvals, PMDA decisions, and orphan/breakthrough designations across 3 regulatory agencies.
Two XGBoost models (early-stage + late-stage), 104 features, temporal validation. Honest AUC 0.968 without regulatory features — 19% above published industry benchmark.